CellPoint (a Galapagos company) believes the future of cell therapy is at the point-of-care, near the patient. The company is developing point-of-care candidate CAR-T therapies that could potentially solve unmet needs of patients with hematological cancer and offer the potential for more rapidly available, affordable treatments. Phase I/II clinical trials with CellPoint candidate CAR-T constructs are currently ongoing in various haematological malignancies.
A fully integrated biotechnology company united around the purpose to transform patient outcomes through life-changing science and innovation. Together with our partners, including Gilead, and collaborators, we are addressing areas of high medical need where we could extend and significantly improve patients' lives. In Oncology we aim to redefine the treatment paradigm targeting cancer from different angles coupled with ingenious manufacturing technologies and other revolutionary approaches.